Xlear files legal response to government’s ‘lawsuit’

NEW YORK, Dec 30, (Agencies): Xlear Inc. filed the company’s response to a Department of Justice lawsuit alleging violations of the Federal Trade Commission Act, among other allegations. The company denied all the Government’s allegations and leveled a series of affirmative defenses at the Government, including violations of Xlear’s First Amendment right to free speech. Nathan Jones, Xlear’s CEO, issued this statement regarding Xlear’s Response:

The United States faces an already raging pandemic and yet another new, wildfire Omicron variant, which studies show is more transmissible, vaccine resistant and as severe as other strains. As a result, across the nation new cases are spiking and breaking records; hospitals are once again overflowing; schools are closing again; not only are we seeing breakthrough infections-we are facing reinfections; the NFL and the NHL have been forced to postpone games; and, there is a real risk that our lives and economy will once again have to close. It’s another COVIDChristmas in America. The nation’s vaccine-only strategy is failing.

Despite this, the Federal Government continues to refuse to even discuss or consider other possible countermeasures-even though they are backed by sound science.

Xlear’s Response outlines a series of studies, including two randomized clinical trials (RCTs) and other clinical and lab data, that more than substantiate Xlear’s statements regarding COVID-19. One recent RCT study found that the use of nasal hygiene in treating COVID-19-infected people over the age of 50 reduced the risk of hospitalization 8-fold.The Government hasn’t meaningfully challenged the legitimacy of these studies-the Government can’t, they paid for some of them and have published some of them. Nor has the Government offered conflicting studies-they can’t. The Government has known about these other countermeasures since June 2020. Yet, the Government still refuses to even discuss or consider them.

The Response we filed also includes a new in vitro study done at Utah State University’s Institute for Antiviral Research. This new in vitro study (using human airway tissue) found that the components in Xlear were significantly more effective antivirals against the Delta strain of COVID-19 than Remdesivir, the Government-approved antiviral medicine. Ironically, the Government alleges it is Xlear that has misled the public.